Close Menu

NEW YORK – Invitae and Pacific Biosciences on Thursday announced a research collaboration that will use long-read next-generation sequencing to help develop diagnostic testing for epilepsy.

Under the terms of the deal, the firms will look for molecular targets and codevelop methods to support new diagnostic epilepsy tests. Invitae will also expand its PacBio sequencing capacity. Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.

In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.

Dec
10
Sponsored by
Tecan

CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology. 

Dec
10
Sponsored by
Illumina

Numerous companies now offer non-invasive prenatal screening (testing), many on different technology platforms.